Physician profile
Michael Lunski
NPI 1063875227
$5,560.89
in general payments reported to CMS, 2019-2025
37 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.55 · 2020: $404 · 2021: $47.73 · 2022: $63.68 · 2023: $1,413 · 2024: $1,463 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,824 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,824.04 |
| Education | $132.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $801.65 | 2020-2025 | Enhertu, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $548.76 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $309.07 | 2023-2025 | |
| Pfizer INC. | $303.97 | 2023-2025 | |
| Gilead Sciences, INC. | $276.64 | 2023-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $259.04 | 2020 | |
| Astellas Pharma US INC | $236.39 | 2022-2025 | Xtandi, Vyloy, Xospata |
| Novartis Pharmaceuticals Corporation | $226.46 | 2023-2025 | |
| Array Biopharma INC | $213.84 | 2023-2025 | Mektovi, Lorbrena, Braftovi |
| E.R. Squibb & Sons, L.L.C. | $197.27 | 2023-2025 | Opdivo, Opdualag |
| Celgene Corporation | $194.66 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $192.02 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $190.67 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $184.43 | 2023-2025 | Tecentriq, Phesgo, Itovebi |
| Janssen Biotech, INC. | $163.37 | 2023-2025 | Darzalex, Rybrevant, Talvey |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $140.44 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Taiho Oncology, INC. | $99.16 | 2023-2025 | |
| Stemline Therapeutics INC. | $95.93 | 2023-2025 | Orserdu |
| Recordati_rare_diseases_inc. | $89.91 | 2025 | Enjaymo |
| Emd Serono, INC. | $89.23 | 2024-2025 | |
| Incyte Corporation | $88.78 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Pharmacyclics LLC, An Abbvie Company | $87.99 | 2023 | Imbruvica, Epkinly |
| Eisai INC. | $83.04 | 2023-2025 | |
| Exelixis INC. | $64.71 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $62.66 | 2025 | Enhertu, Datroway |
| Aveo Pharmaceuticals, INC. | $37.55 | 2023-2024 | Fotivda |
| Servier Pharmaceuticals LLC | $34.97 | 2024-2025 | |
| Amgen INC. | $31.39 | 2023 | Vectibix, Xgeva, Nplate |
| Tersera Therapeutics LLC | $30.53 | 2024-2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $23.07 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $22.13 | 2024 | Onivyde |
| Coherus Oncology, INC. | $20.68 | 2023 | |
| Boston Scientific Corporation | $16.04 | 2025 | Spaceoar Vue System - 10ml |
| Mirati Therapeutics, INC. | $15.84 | 2023 | Krazati |
| Telix Pharmaceuticals | $15.53 | 2024 | Illuccix |
| Helsinn Therapeutics (U.S.), INC. | $13.12 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lunski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.